Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Change in Cash (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Change in Cash for 7 consecutive years, with -$4.5 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Change in Cash fell 207.54% year-over-year to -$4.5 million, compared with a TTM value of -$3.4 million through Dec 2019, down 139.6%, and an annual FY2024 reading of $5.7 million, up 7647.37% over the prior year.
  • Change in Cash was -$4.5 million for Q4 2019 at Larimar Therapeutics, down from $4.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $48.8 million in Q1 2015 and bottomed at -$44.8 million in Q3 2015.
  • Average Change in Cash over 5 years is -$607950.0, with a median of -$37000.0 recorded in 2015.
  • Peak annual rise in Change in Cash hit 1546.36% in 2015, while the deepest fall reached 522.1% in 2015.
  • Year by year, Change in Cash stood at -$3.2 million in 2015, then soared by 336.46% to $7.5 million in 2016, then skyrocketed by 188.13% to $21.6 million in 2017, then plummeted by 80.59% to $4.2 million in 2018, then tumbled by 207.54% to -$4.5 million in 2019.
  • Business Quant data shows Change in Cash for LRMR at -$4.5 million in Q4 2019, $4.1 million in Q3 2019, and $8.6 million in Q2 2019.